Amrutanjan Health Care Ltd. released its investor presentation for the quarter ended June 30, 2024, highlighting strong segment performances, with a 10.0% value growth and 4.3% volume growth in the OTC Head category, and a substantial 17.6% volume growth in the Body category, driven by product enhancements and consumer acceptance.